NCT06203821
Study of Perioperative NP137 and FOLFIRINOX in Resectable Pancreatic Cancer
Not Yet Recruiting · Phase 1 · Aram Hezel · registry updated 2026-02-05
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
The objective of this study is to investigate whether adding the study drug, NP137, to a patient's treatment regimen (before surgery and in combination with chemotherapy afterward) can alter the behavior of pancreatic cancer..
Inclusion
- Subjects with imaging suggesting resectable pancreatic cancer and without strong evidence of metastatic disease.
- Accept to undergo biopsy for initial diagnosis and research purposes. NOTE: For patients who already have cytologically or histologically confirmed resectable pancreatic ductal adenocarcinoma, they must agree to undergo research biopsy.
- Cytologically or histologically confirmed resectable pancreatic ductal adenocarcinoma.
- Confirmed resectable pancreatic ductal adenocarcinoma by treating surgeon.
- No prior systemic therapy, radiation therapy, or resection for pancreatic cancer.
- Written informed consent to participate in the trial.
Exclusion
- Patients with borderline or locally advanced or metastatic pancreatic cancer as deemed by treating surgeon.
- Patients who are unlikely to undergo surgery, and systemic therapy, in the opinion of the treating investigators.
- Patients with grade ≥ 2 peripheral neuropathy.
- Patients with known Gilbert's Syndrome, Dihydropyrimidine dehydrogenase (DPD) deficiency, or homozygosity for UGAT1A1\*28 polymorphism. Note: evaluation for these is not required.
- Patients with active duodenal or gastric ulcers, or direct tumor invasion of the bowel or stomach by endoscopic evaluation. Note: patients with previous ulcers without active bleeding or symptoms are eligible.
- Patients with serious active infection within 2 weeks prior to enrollment (e.g. requiring hospitalization and/or intravenous \[IV\] antibiotics) or currently receiving oral or IV antibiotics for the treatment of infection. Patients receiving prophylactic antibiotics are eligible.